查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2004724

藥物研發外包市場：2026年至2032年全球市場預測（依服務類型、藥物研發階段、工作流程、藥物類型、應用領域及最終用戶分類）

Drug Discovery Outsourcing Market by Service Type, Discovery Phase, Workflow, Drug Type, Application Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物研發外包市場價值將達到 42.9 億美元，到 2026 年將成長至 46.5 億美元，到 2032 年將達到 77.1 億美元，複合年成長率為 8.71%。

主要市場統計數據
基準年 2025 42.9億美元
預計年份：2026年 46.5億美元
預測年份：2032年 77.1億美元
複合年成長率 (%) 8.71%

重組後的藥物研發外包生態系統的背景訊息，該生態系統由技術融合、戰略夥伴關係和業務永續營運所塑造。

全球藥物研發格局正經歷著結構性變革時期，其驅動力包括技術飛躍、贊助商優先事項的轉變以及不斷變化的經濟壓力。外包已成為製藥和生物技術公司利用內部不易獲得的專業知識、加快研發進度、快速獲得專業能力、管理研發風險以及控制營運成本的核心策略工具。擁有深厚生物學專業知識、合成化學能力和先進資料管理技能的外部供應商，正日益被視為轉化研究合作夥伴，而不僅僅是供應商。

人工智慧整合、自動化實驗平台、模組化合作夥伴關係、供應鏈彈性以及監管參與正在如何重塑您的外包策略？

近年來，我們見證了一系列變革性變化，這些變化正在重新定義藥物研發外包的框架，並改變申辦者評估外部合作夥伴的方式。首先，人工智慧和先進分析技術融入先導化合物的識別和最佳化工作流程，正在加速假設的生成，實現化合物庫的虛擬篩選，並優先進行資訊價值更高的實驗。這種變化不僅僅關乎速度，它從根本上改變了藥物研發專案的設計，使實驗更具針對性，資源分配更加有效率。

本分析檢視了 2025 年美國關稅變化對供應鏈、採購實務和外包連續性的多層次營運影響。

2025年推出的政策變革和貿易措施為依賴跨境供應鏈獲取試劑、儀器和中間體化合物的機構帶來了切實的營運挑戰。影響某些實驗室耗材、特殊化學品和部分儀器組件的關稅調整增加了整體成本，並導致關鍵投入品的前置作業時間出現波動。對許多贊助商和供應商而言，最直接的影響是需要修訂採購計畫和供應商協議，以降低關稅波動和運輸中斷的風險。

為了促進與供應商的合作，我們透過繪製服務類型、藥物發現階段、工作流程、藥物模式、治療應用和最終用戶趨勢圖，創建了詳細的見解。

服務類型細分揭示了贊助商在哪些方面集中投入外包成本和預期收益。根據服務類型，市場被分為三大類：生物服務、化學服務和資料管理服務。生物服務進一步細分為檢測方法開發和生物測試，反映了對穩健的轉化型檢測方法以及體外/體內測試能力的需求。化學服務進一步細分為客製化合成和製程研發，凸顯了對客製化化學解決方案和可擴展合成通路開發的持續需求。資料管理服務進一步細分為生物資訊學和資料整合，強調整合多體學和篩檢資料的能力如今已成為服務提供者的競爭優勢。

對美洲、歐洲、中東和非洲以及亞太地區如何以獨特的方式影響外包合作夥伴的選擇和業務策略進行區域分析。

區域趨勢影響策略外包的選擇，每個區域都有其獨特的促進因素和限制因素。在生物技術創新中心和創業投資專案集中的美洲地區，由於需要快速且靈活的夥伴關係模式，整合藥物研發服務和先進資料分析能力的需求仍然強勁。在此背景下，擁有深厚的治療專業知識、強大的數據平台和豐富的監管經驗的供應商往往是快速開發專案的首選合作夥伴。

關鍵企業級趨勢表明，整合平台、專家夥伴關係和卓越的合規性如何決定競爭差異化和客戶偏好。

企業層面的競爭格局日益取決於企業整合跨學科能力並維持高品質標準和合規性的能力。領先的合約研究組織 (CRO) 和專業供應商正透過投資專有平台、與科技公司建立策略合作夥伴關係以及在小分子和生物製藥項目方面積累的豐富經驗來脫穎而出。擁有內部計算科學團隊和檢驗的生物資訊流程的公司能夠提供更具預測性的決策支援並縮短迭代周期。

領導者用來最佳化供應商韌性、資料互通性、合約柔軟性、監管合規性和技術合格的實用建議。

產業領導者可以採取以下幾個切實可行的步驟來增強其外包能力，並從外部夥伴關係中獲得更大價值。首先，透過對多家供應商進行關鍵能力認證，並制定緊急時應對計畫以減少對單一供應商的依賴，從而實現供應商生態系統的多元化。這種方法可以在不犧牲專業方法取得的前提下提高韌性。其次，投資於可互通的資料標準和安全的雲端架構，以實現委託方和外部實驗室之間的無縫交接，從而減少返工並加快決策速度。

採用嚴謹的混合方法研究途徑，結合高階主管的訪談、二手技術審查、能力映射和情境分析，得出可操作的見解。

本概要的研究結合了定性和定量方法，以確保得出可靠且令人信服的見解。主要研究包括對贊助機構和服務供應商的高級研發主管、採購經理和技術經理進行結構化訪談，以收集關於能力需求、供應商選擇標準和區域營運限制的第一手觀點。此外，也諮詢了監管事務專家和供應鏈專家，以分析政策和物流方面的影響。

簡潔的結論強調，科學的嚴謹性、全面的資料系統和策略性的風險管理對於外包藥物研發專案的成功至關重要。

總而言之，藥物研發外包環境正日趨成熟，成為一個更加一體化、數據驅動的生態系統，其中戰略夥伴關係的選擇對專案進度和科研成果有著顯著影響。計算化學、自動化檢測系統和數據整合技術的進步，使得能夠提供可重複、可解釋的資料集，並將輸出結果轉化為清晰的後續實驗步驟的供應商變得愈發重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 藥物研發外包市場：依服務類型分類

  • 生物服務
    • 檢測方法開發
    • 生物學檢查
  • 化學服務
    • 客製合成
    • 製程研究與開發
  • 資料管理服務
    • 生物資訊學
    • 資料整合

第9章 藥物研發外包市場：依藥物研發階段分類

  • 先導藥物最適化
    • 化合物篩檢
    • 基於結構的藥物發現
  • 目標識別
    • 生物標記生成
    • 基因組定序方法

第10章 藥物研發外包市場：依工作流程分類

  • 先導化合物篩選及候選化合物最佳化
  • 臨床前開發
  • 目標識別和篩檢
  • 目標檢驗和功能資訊學

第11章 藥物研發外包市場：依藥物類型分類

  • 聚合物化合物
    • 生技藥品
    • 生物相似藥
  • 小分子藥物

第12章 藥物研發外包市場：依應用領域分類

  • 心血管疾病
    • 心臟衰竭
    • 高血壓
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌

第13章 藥物研發外包市場：依最終用戶分類

  • 合約研究組織（CRO）
    • 全方位CRO服務
    • 專業合約研究組織
  • 製藥和生物技術公司
    • 主要企業
    • 小型企業
  • 研究機構
    • 學術機構
    • 政府附屬研究機構

第14章 藥物研發外包市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 藥物研發外包市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 藥物研發外包市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國藥物研發外包市場

第18章：中國的藥物研發外包市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies Inc.
  • Aragen Life Sciences Ltd.
  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Global, Inc.
  • Dalton Pharma Services
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • GenScript BIoTech Corporation
  • HD Biosciences Co., Ltd.
  • IQVIA
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Oncodesign Services
  • Personalis, Inc.
  • Pfizer Inc.
  • PPD Inc.
  • Promega Corporation
  • Revvity Discovery Limited
  • Sanofi SA
  • STC Biologics Inc.
  • Syngene International Ltd.
  • TCG Lifesciences Pvt. Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-742BD517D92E

The Drug Discovery Outsourcing Market was valued at USD 4.29 billion in 2025 and is projected to grow to USD 4.65 billion in 2026, with a CAGR of 8.71%, reaching USD 7.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.29 billion
Estimated Year [2026] USD 4.65 billion
Forecast Year [2032] USD 7.71 billion
CAGR (%) 8.71%

Contextual introduction to the reshaped drug discovery outsourcing ecosystem shaped by technology convergence, strategic partnerships, and operational resilience

The global drug discovery environment is undergoing a period of structural change driven by technological breakthroughs, evolving sponsor priorities, and shifting economic pressures. Outsourcing has become a core strategic lever for pharmaceutical and biotechnology organizations to access specialized capabilities rapidly, manage development risk, and control operational costs while accelerating timelines through expertise not readily available in-house. External providers that combine deep biological expertise, synthetic chemistry capabilities, and advanced data management are increasingly viewed as partners in translational research rather than simple vendors.

Concurrently, the rise of machine learning, cloud-native informatics, and high-content screening platforms has altered expectations around data interoperability and decision velocity. Sponsors now prioritize partners who can ingest heterogeneous data streams, apply robust analytic pipelines, and translate outputs into clear experimental next steps. This shift favors integrated service models that bridge wet-lab proficiency with computational workflows. Moreover, the complexity of modern modalities-ranging from engineered biologics to precision small molecules-places a premium on CROs and specialty service firms that demonstrate regulatory acumen and scalable operational practices.

As organizations balance the need for innovation with tighter procurement scrutiny and supply chain resilience concerns, outsourcing choices hinge on flexibility, quality, and the ability to co-develop programs across discovery phases. The remainder of this summary outlines the most consequential forces reshaping outsourcing strategies and offers pragmatic guidance for leaders navigating this transformed environment.

How AI integration, automated laboratory platforms, modular partnering, supply chain resilience, and regulatory engagement are reshaping outsourcing strategies

Recent years have seen a series of transformative shifts that are redefining the contours of drug discovery outsourcing and changing how sponsors evaluate external partners. First, the integration of AI and advanced analytics into lead identification and optimization workflows is accelerating hypothesis generation, enabling virtual triage of compound libraries and prioritizing experiments that yield higher informational value. This change is not merely about speed; it is about altering the design of discovery programs so that experiments are more targeted and resource allocation is more efficient.

Second, the parallel advancement of laboratory automation and miniaturized assays has expanded throughput while improving reproducibility. This technological progression allows service providers to offer scalable assay cascades that feed richer, more standardized data into informatics platforms. Third, the industry has embraced modular business models in which sponsors combine full-service CRO relationships with boutique specialist engagements to access niche capabilities without sacrificing program continuity.

Fourth, supply chain resiliency and geopolitical factors have prompted many organizations to reconsider sourcing strategies, resulting in increased interest in regional capacity and single-source risk mitigation. Finally, regulatory authorities are engaging earlier in development conversations around complex modalities and biomarker-driven programs, which raises the bar for outsourced partners to demonstrate methodological rigor, traceability, and compliance. Together, these shifts are producing a landscape where capability depth, data integration, and strategic alignment determine long-term partnership value.

Analyzing the layered operational consequences of the United States tariff changes in 2025 on supply chains, procurement practices, and outsourcing continuity

Policy changes and trade measures introduced in 2025 have introduced tangible operational considerations for organizations that rely on cross-border supply chains for reagents, instrumentation, and intermediate compounds. Tariff adjustments affecting certain classes of laboratory consumables, specialized chemicals, and selected instrumentation components have increased landed costs and introduced variability in lead times for critical inputs. For many sponsors and providers, the immediate consequence has been a re-evaluation of sourcing maps and vendor contracts to reduce exposure to tariff volatility and shipping disruptions.

In practical terms, some discovery groups have accelerated qualification of secondary suppliers and moved to dual-sourcing strategies to maintain experimental continuity. Others have prioritized vendor partnerships that include local inventory stocking or regional manufacturing capabilities to limit the impact of import duties and customs delays. Contractual clauses related to price pass-through, force majeure, and delivery SLAs have become focal points during procurement negotiations, reflecting the need to allocate risk explicitly.

Operational teams are also adjusting project timelines and buffer inventories where possible to accommodate intermittent delays, while finance and procurement functions are recalibrating budgeting assumptions to account for higher variable input costs. Importantly, the tariff-driven pressures are reinforcing pre-existing strategic trends toward regionalization and nearshoring for certain high-volume or time-sensitive processes, without necessarily undoing the advantages of global capability networks that are required for specialized technologies and rare expertise.

Granular segmentation-driven insights that map service types, discovery phases, workflows, drug modalities, therapeutic applications, and end-user dynamics for vendor alignment

Service-type segmentation reveals where sponsors are concentrating their outsourcing spend and expectations. Based on Service Type, the market is studied across Biological Services, Chemical Services, and Data Management Services. The Biological Services is further studied across Assay Development and Biological Testing, reflecting demand for robust, translatable assays and in vitro/in vivo testing capacities. The Chemical Services is further studied across Custom Synthesis and Process R&D, highlighting the continued need for bespoke chemistry solutions and scalable route development. The Data Management Services is further studied across Bioinformatics and Data Integration, underscoring that the ability to harmonize multi-omic and screening data is now a competitive differentiator for providers.

Discovery-phase segmentation clarifies where specialized competencies matter most during program progression. Based on Discovery Phase, the market is studied across Lead Optimization and Target Identification. The Lead Optimization is further studied across Compound Screening and Structure-Based Drug Design, indicating a focus on iterative chemotype refinement and computationally guided selection. The Target Identification is further studied across Biomarker Discovery and Genomic Sequencing Methods, reflecting investments in molecular characterization and patient-stratified approaches.

Workflow-focused segmentation maps capabilities to program milestones. Based on Workflow, the market is studied across Lead Identification & Candidate Optimization, Preclinical Development, Target Identification & Screening, and Target Validation & Functional Informatics, which helps sponsors align provider skill sets to project phases. Drug-type segmentation separates modality-specific requirements. Based on Drug Type, the market is studied across Large Molecules and Small Molecules. The Large Molecules is further studied across Biologics and Biosimilar, indicating divergence in analytical demands and manufacturing pathways. Application-area segmentation aligns therapeutic focus with technical needs. Based on Application Area, the market is studied across Cardiovascular Diseases, Infectious Diseases, and Oncology. The Cardiovascular Diseases is further studied across Heart Failure and Hypertension. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Hematological Malignancies and Solid Tumors, emphasizing the need for disease-specific assay suites. End-user segmentation clarifies channel dynamics and decision drivers. Based on End User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Research Institutes. The Contract Research Organizations is further studied across Full-Service CROs and Specialty CROs. The Pharmaceutical & Biotechnology Companies is further studied across Large Enterprises and SMEs. The Research Institutes is further studied across Academic Institutions and Government Research Centers, which affects procurement cycles and collaboration incentives.

These segmentation lenses collectively provide a granular way to evaluate provider fit for discrete program requirements, enabling sponsors to match service scope, technological depth, and regulatory alignment to the specific stage and therapeutic focus of their projects.

Regional intelligence on how Americas, Europe Middle East & Africa, and Asia-Pacific each distinctively influence outsourcing partner selection and operational strategies

Regional dynamics are shaping strategic choices for outsourcing, with distinct drivers and constraints in each geography. Americas continue to exhibit strong demand for integrated discovery services and advanced data analytics capabilities, driven by a concentration of biotech innovation hubs and venture-backed programs that demand speed and flexible partnership models. In this context, providers that combine deep therapeutic expertise with robust data platforms and regulatory familiarity tend to be preferred partners for fast-moving development programs.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization and access to specialized translational centers support collaboration across borders, while localized capacity and talent pools differ markedly between Western and emerging markets. Sponsors operating in this region emphasize rigorous compliance frameworks and provenance for biological materials, along with collaborative arrangements that bridge academic innovation and industrial development.

Asia-Pacific remains a focal point for both cost-efficient laboratory services and rapidly maturing centers of scientific excellence, particularly in biologics, synthetic chemistry, and high-throughput screening. Investments in regional manufacturing capacity and local regulatory pathways are reducing friction for programs that require scale and speed in late-stage preclinical work. Across all regions, the interplay between local capabilities, regulatory expectations, and supply chain resilience informs partner selection and contracting models.

Key company-level dynamics showing how integrated platforms, specialist partnerships, and compliance excellence determine competitive differentiation and client preference

Company-level competitive dynamics are increasingly defined by the ability to integrate cross-disciplinary capabilities while maintaining high standards of quality and compliance. Leading contract research organizations and specialty providers differentiate themselves through investments in proprietary platforms, strategic alliances with technology firms, and demonstrated experience across both small molecule and biologics programs. Firms with embedded computational teams and validated bioinformatics pipelines are able to offer more predictive decision support and shorter iteration cycles.

Partnership models matter: full-service providers that can manage end-to-end discovery workflows retain appeal for sponsors seeking program continuity, whereas specialty CROs remain essential for complex assays, custom chemistry, and novel modality expertise. Collaboration between larger integrators and niche specialists is a common pattern, where the larger firm coordinates program delivery while the specialist contributes critical technical depth. Additionally, companies that emphasize transparent quality systems, traceable data management practices, and clear regulatory documentation have a competitive advantage when supporting translational or biomarker-driven programs.

Strategic moves such as platform licensing, geographic expansion, and co-investment in localized manufacturing or reagent supply chains are practical ways companies are responding to client needs. Ultimately, vendor selection reflects a trade-off between breadth of services, depth of technical competence, and the ability to align commercial terms to program risk and timelines.

Actionable recommendations for leaders to optimize supplier resilience, data interoperability, contracting flexibility, regulatory alignment, and technology qualification

Industry leaders can take several pragmatic steps to strengthen their outsourcing posture and extract greater value from external partnerships. First, diversify supplier ecosystems by qualifying multiple providers for critical capabilities and establishing contingency plans that reduce single-source exposure. This approach improves resilience without sacrificing access to specialized methods. Second, invest in interoperable data standards and secure cloud architectures that allow seamless handoffs between sponsors and external laboratories, thereby reducing rework and accelerating decision-making.

Third, adopt flexible contracting frameworks that align incentives across milestones and allow scope adjustments as scientific hypotheses evolve. Such models can include phased engagements with clear go/no-go criteria and pre-negotiated options for scale-up. Fourth, prioritize vendors with demonstrated regulatory experience in complex modalities and biomarker-driven trials to minimize downstream compliance risk. Fifth, consider regional capacity strategies that combine local inventory control with strategic global partners to mitigate tariff and logistics exposure.

Finally, cultivate internal capabilities for rapid technology assessment and vendor qualification, including structured scorecards that evaluate scientific rigor, data governance, quality systems, and cost transparency. By combining operational discipline with strategic partnership design, organizations can convert outsourcing from a transactional expense into a competitive advantage that accelerates discovery while managing risk.

Rigorous mixed-methods research approach combining executive interviews, secondary technical review, capability mapping, and scenario analysis to produce actionable intelligence

The research underpinning this summary combined qualitative and quantitative approaches to ensure robust, defensible insights. Primary research included structured interviews with senior R&D executives, procurement leaders, and technical heads across sponsor organizations and service providers to capture first-hand perspectives on capability requirements, vendor selection criteria, and regional operational constraints. These interviews were complemented by expert consultations with regulatory affairs professionals and supply chain specialists to contextualize policy and logistics impacts.

Secondary research incorporated published scientific literature, regulatory guidance, company disclosures, patent landscapes, and technology white papers to triangulate trends in assay platforms, computational adoption, and modality-specific development practices. Data synthesis emphasized validation across multiple sources to minimize bias and ensure that conclusions reflect convergent evidence rather than single-source assumptions.

Analytical methods included capability mapping against the segmentation schema and scenario analysis to explore how tariffs, supply disruptions, and technological adoption alter risk profiles. The methodology prioritized transparency in assumptions and used iterative review cycles with domain experts to refine interpretation and recommendations. Throughout, emphasis was placed on actionable insights that stakeholders can apply to procurement strategy, partnership design, and operational planning.

Concise conclusion emphasizing the necessity of scientific rigor, integrated data systems, and strategic risk management for successful outsourced discovery programs

In summary, the drug discovery outsourcing landscape is maturing into a more integrated, data-driven ecosystem where strategic partnership choices materially affect program velocity and scientific outcomes. Advances in computational chemistry, automated assay systems, and data integration technologies are elevating the importance of providers that can deliver reproducible, interpretable datasets and translate those outputs into defined experimental next steps.

Concurrently, policy developments and supply chain pressures have highlighted the need for diversified sourcing strategies and regional operational planning. Sponsors that proactively qualify alternative suppliers, rationalize inventory strategies, and negotiate adaptive contracting terms will be better positioned to sustain discovery momentum during periods of external disruption. Company differentiation is rooted in the capacity to combine deep technical expertise with transparent quality and data governance practices that support regulatory engagement and program scalability.

Ultimately, successful outsourcing in the current era requires a balance of scientific rigor, technological integration, and pragmatic risk management. Organizations that align their partner ecosystem to these principles can accelerate discovery, reduce avoidable delays, and create more predictable pathways from hypothesis to candidate selection.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Outsourcing Market, by Service Type

  • 8.1. Biological Services
    • 8.1.1. Assay Development
    • 8.1.2. Biological Testing
  • 8.2. Chemical Services
    • 8.2.1. Custom Synthesis
    • 8.2.2. Process R&D
  • 8.3. Data Management Services
    • 8.3.1. Bioinformatics
    • 8.3.2. Data Integration

9. Drug Discovery Outsourcing Market, by Discovery Phase

  • 9.1. Lead Optimization
    • 9.1.1. Compound Screening
    • 9.1.2. Structure-Based Drug Design
  • 9.2. Target Identification
    • 9.2.1. Biomarker Discovery
    • 9.2.2. Genomic Sequencing Methods

10. Drug Discovery Outsourcing Market, by Workflow

  • 10.1. Lead Identification & Candidate Optimization
  • 10.2. Preclinical Development
  • 10.3. Target Identification & Screening
  • 10.4. Target Validation & Functional Informatics

11. Drug Discovery Outsourcing Market, by Drug Type

  • 11.1. Large Molecules
    • 11.1.1. Biologics
    • 11.1.2. Biosimillar
  • 11.2. Small Molecules

12. Drug Discovery Outsourcing Market, by Application Area

  • 12.1. Cardiovascular Diseases
    • 12.1.1. Heart Failure
    • 12.1.2. Hypertension
  • 12.2. Infectious Diseases
    • 12.2.1. Bacterial Infections
    • 12.2.2. Viral Infections
  • 12.3. Oncology
    • 12.3.1. Hematological Malignancies
    • 12.3.2. Solid Tumors

13. Drug Discovery Outsourcing Market, by End User

  • 13.1. Contract Research Organizations
    • 13.1.1. Full-Service CROs
    • 13.1.2. Specialty CROs
  • 13.2. Pharmaceutical & Biotechnology Companies
    • 13.2.1. Large Enterprises
    • 13.2.2. SMEs
  • 13.3. Research Institutes
    • 13.3.1. Academic Institutions
    • 13.3.2. Government Research Centers

14. Drug Discovery Outsourcing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Drug Discovery Outsourcing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Drug Discovery Outsourcing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Drug Discovery Outsourcing Market

18. China Drug Discovery Outsourcing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agilent Technologies Inc.
  • 19.6. Aragen Life Sciences Ltd.
  • 19.7. BPS Bioscience, Inc.
  • 19.8. Celentyx Ltd.
  • 19.9. Charles River Laboratories International, Inc.
  • 19.10. Covance, Inc.
  • 19.11. Crown Bioscience, Inc.
  • 19.12. Curia Global, Inc.
  • 19.13. Dalton Pharma Services
  • 19.14. Eurofins Scientific
  • 19.15. Evotec SE
  • 19.16. Explicyte
  • 19.17. GenScript Biotech Corporation
  • 19.18. HD Biosciences Co., Ltd.
  • 19.19. IQVIA
  • 19.20. Jubilant Biosys Ltd.
  • 19.21. Laboratory Corporation of America Holdings
  • 19.22. Merck & Co., Inc.
  • 19.23. Oncodesign Services
  • 19.24. Personalis, Inc.
  • 19.25. Pfizer Inc.
  • 19.26. PPD Inc.
  • 19.27. Promega Corporation
  • 19.28. Revvity Discovery Limited
  • 19.29. Sanofi S.A.
  • 19.30. STC Biologics Inc.
  • 19.31. Syngene International Ltd.
  • 19.32. TCG Lifesciences Pvt. Limited
  • 19.33. Thermo Fisher Scientific Inc.
  • 19.34. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292.